JP2019504018A5 - - Google Patents

Info

Publication number

JP2019504018A5

JP2019504018A5 JP2018531554A JP2018531554A JP2019504018A5 JP 2019504018 A5 JP2019504018 A5 JP 2019504018A5 JP 2018531554 A JP2018531554 A JP 2018531554A JP 2018531554 A JP2018531554 A JP 2018531554A JP 2019504018 A5 JP2019504018 A5 JP 2019504018A5

Authority

JP

Japan

Prior art keywords

alkyl

compound according

item

deficiency

compound

Prior art date

2016-12-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 180
• 125000000217 alkyl group Chemical group 0.000 claims description 79
• 150000003839 salts Chemical class 0.000 claims description 39
• 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 claims description 31
• 239000000203 mixture Substances 0.000 claims description 22
• 239000000090 biomarker Substances 0.000 claims description 15
• 125000001188 haloalkyl group Chemical group 0.000 claims description 13
• 208000013200 Stress disease Diseases 0.000 claims description 9
• 230000007812 deficiency Effects 0.000 claims description 9
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
• 230000036542 oxidative stress Effects 0.000 claims description 9
• AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 8
• 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
• 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 6
• QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 6
• 208000006011 Stroke Diseases 0.000 claims description 6
• 208000029560 autism spectrum disease Diseases 0.000 claims description 6
• 208000035475 disorder Diseases 0.000 claims description 6
• 208000011580 syndromic disease Diseases 0.000 claims description 6
• 206010011878 Deafness Diseases 0.000 claims description 5
• 208000023105 Huntington disease Diseases 0.000 claims description 5
• 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims description 5
• 229910052799 carbon Inorganic materials 0.000 claims description 5
• 230000010370 hearing loss Effects 0.000 claims description 5
• 231100000888 hearing loss Toxicity 0.000 claims description 5
• 208000016354 hearing loss disease Diseases 0.000 claims description 5
• 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 5
• 230000002401 inhibitory effect Effects 0.000 claims description 5
• 208000002780 macular degeneration Diseases 0.000 claims description 5
• 229910052757 nitrogen Inorganic materials 0.000 claims description 5
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
• 125000001424 substituent group Chemical group 0.000 claims description 5
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
• 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 4
• 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 4
• 206010048804 Kearns-Sayre syndrome Diseases 0.000 claims description 4
• 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 4
• 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 claims description 4
• 201000009035 MERRF syndrome Diseases 0.000 claims description 4
• 208000035719 Maculopathy Diseases 0.000 claims description 4
• 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 claims description 4
• 208000014844 Mitochondrial neurogastrointestinal encephalomyopathy Diseases 0.000 claims description 4
• 206010065271 Mitochondrial neurogastrointestinal encephalopathy Diseases 0.000 claims description 4
• 206010061323 Optic neuropathy Diseases 0.000 claims description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
• 230000006378 damage Effects 0.000 claims description 4
• 125000001072 heteroaryl group Chemical group 0.000 claims description 4
• 125000000623 heterocyclic group Chemical group 0.000 claims description 4
• 208000028867 ischemia Diseases 0.000 claims description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
• 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
• 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
• 208000012268 mitochondrial disease Diseases 0.000 claims description 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
• 208000020911 optic nerve disease Diseases 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
• 208000024827 Alzheimer disease Diseases 0.000 claims description 3
• 206010003591 Ataxia Diseases 0.000 claims description 3
• 206010058892 Carnitine deficiency Diseases 0.000 claims description 3
• 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 3
• 208000018737 Parkinson disease Diseases 0.000 claims description 3
• 201000007737 Retinal degeneration Diseases 0.000 claims description 3
• 230000001919 adrenal effect Effects 0.000 claims description 3
• 206010012601 diabetes mellitus Diseases 0.000 claims description 3
• 201000010099 disease Diseases 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• -1 methyl compound Chemical class 0.000 claims description 3
• 201000003645 multiple acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 3
• 201000001119 neuropathy Diseases 0.000 claims description 3
• 230000007823 neuropathy Effects 0.000 claims description 3
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
• 208000007056 sickle cell anemia Diseases 0.000 claims description 3
• 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 3
• 210000004885 white matter Anatomy 0.000 claims description 3
• 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims description 2
• 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 2
• 208000036640 Asperger disease Diseases 0.000 claims description 2
• 201000006062 Asperger syndrome Diseases 0.000 claims description 2
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
• 206010003805 Autism Diseases 0.000 claims description 2
• 208000020706 Autistic disease Diseases 0.000 claims description 2
• 208000020925 Bipolar disease Diseases 0.000 claims description 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
• 108700005857 Carnitine palmitoyl transferase 1A deficiency Proteins 0.000 claims description 2
• 208000005359 Carnitine palmitoyl transferase 1A deficiency Diseases 0.000 claims description 2
• 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 claims description 2
• 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims description 2
• 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
• 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
• 208000010354 Coenzyme Q10 deficiency Diseases 0.000 claims description 2
• 208000021075 Creatine deficiency syndrome Diseases 0.000 claims description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
• 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 2
• 201000010374 Down Syndrome Diseases 0.000 claims description 2
• 102000015782 Electron Transport Complex III Human genes 0.000 claims description 2
• 108010024882 Electron Transport Complex III Proteins 0.000 claims description 2
• 208000010412 Glaucoma Diseases 0.000 claims description 2
• 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims description 2
• 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 claims description 2
• 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims description 2
• 101000603761 Homo sapiens Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Proteins 0.000 claims description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
• 208000025069 Juvenile Huntington disease Diseases 0.000 claims description 2
• 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 claims description 2
• 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims description 2
• 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims description 2
• 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims description 2
• 208000014413 Maternally-inherited diabetes and deafness Diseases 0.000 claims description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
• 206010059521 Methylmalonic aciduria Diseases 0.000 claims description 2
• 206010059396 Mitochondrial DNA depletion Diseases 0.000 claims description 2
• 206010050029 Mitochondrial cytopathy Diseases 0.000 claims description 2
• 208000019022 Mood disease Diseases 0.000 claims description 2
• 206010028980 Neoplasm Diseases 0.000 claims description 2
• 102100035196 POLG alternative reading frame Human genes 0.000 claims description 2
• 208000013234 Pearson syndrome Diseases 0.000 claims description 2
• 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 claims description 2
• 208000012202 Pervasive developmental disease Diseases 0.000 claims description 2
• 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims description 2
• 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims description 2
• 206010038540 Renal tubular necrosis Diseases 0.000 claims description 2
• 208000017442 Retinal disease Diseases 0.000 claims description 2
• 206010057430 Retinal injury Diseases 0.000 claims description 2
• 206010038923 Retinopathy Diseases 0.000 claims description 2
• 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
• 208000016620 Tourette disease Diseases 0.000 claims description 2
• 206010047571 Visual impairment Diseases 0.000 claims description 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
• 201000011510 cancer Diseases 0.000 claims description 2
• 201000004010 carnitine palmitoyltransferase I deficiency Diseases 0.000 claims description 2
• 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 claims description 2
• 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
• 208000035110 classic form autosomal dominant optic atrophy Diseases 0.000 claims description 2
• 206010016256 fatigue Diseases 0.000 claims description 2
• 208000016361 genetic disease Diseases 0.000 claims description 2
• 230000002068 genetic effect Effects 0.000 claims description 2
• 208000005017 glioblastoma Diseases 0.000 claims description 2
• 208000006443 lactic acidosis Diseases 0.000 claims description 2
• 230000008774 maternal effect Effects 0.000 claims description 2
• 201000003694 methylmalonic acidemia Diseases 0.000 claims description 2
• 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 2
• 230000002438 mitochondrial effect Effects 0.000 claims description 2
• 201000006417 multiple sclerosis Diseases 0.000 claims description 2
• 201000006938 muscular dystrophy Diseases 0.000 claims description 2
• 230000035772 mutation Effects 0.000 claims description 2
• 230000004770 neurodegeneration Effects 0.000 claims description 2
• 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 2
• 206010030875 ophthalmoplegia Diseases 0.000 claims description 2
• 238000007254 oxidation reaction Methods 0.000 claims description 2
• 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
• 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 claims description 2
• 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims description 2
• 201000010384 renal tubular acidosis Diseases 0.000 claims description 2
• 230000035806 respiratory chain Effects 0.000 claims description 2
• 201000000980 schizophrenia Diseases 0.000 claims description 2
• 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 2
• 210000000278 spinal cord Anatomy 0.000 claims description 2
• 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 2
• 208000029257 vision disease Diseases 0.000 claims description 2
• 230000004393 visual impairment Effects 0.000 claims description 2
• 206010010904 Convulsion Diseases 0.000 claims 2
• 208000024412 Friedreich ataxia Diseases 0.000 claims 2
• 208000024825 childhood disintegrative disease Diseases 0.000 claims 2
• 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 1
• 208000012639 Balance disease Diseases 0.000 claims 1
• 208000016621 Hearing disease Diseases 0.000 claims 1
• 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
• 208000001089 Multiple system atrophy Diseases 0.000 claims 1
• 208000021642 Muscular disease Diseases 0.000 claims 1
• 201000009623 Myopathy Diseases 0.000 claims 1
• 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 claims 1
• 208000029028 brain injury Diseases 0.000 claims 1
• 231100000518 lethal Toxicity 0.000 claims 1
• 230000001665 lethal effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 19
• 125000000753 cycloalkyl group Chemical group 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
• 239000012530 fluid Substances 0.000 description 5
• 210000002381 plasma Anatomy 0.000 description 5
• 230000002861 ventricular Effects 0.000 description 5
• 102000018832 Cytochromes Human genes 0.000 description 4
• 108010052832 Cytochromes Proteins 0.000 description 4
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
• 235000017471 coenzyme Q10 Nutrition 0.000 description 3
• ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
• WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
• 0 *C(C(C(*)=C1*)=O)=C(*)C1=O Chemical compound *C(C(C(*)=C1*)=O)=C(*)C1=O 0.000 description 1
• HWKRAUXFMLQKLS-UHFFFAOYSA-N 2-oxidanylidenepropanoic acid Chemical compound CC(=O)C(O)=O.CC(=O)C(O)=O HWKRAUXFMLQKLS-UHFFFAOYSA-N 0.000 description 1
• KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• QGDLWQFFQHCHEJ-UHFFFAOYSA-N CC(C(C(C)=C1CCCCCCCCCCOCC(F)(F)F)=O)=C(C)C1=O Chemical compound CC(C(C(C)=C1CCCCCCCCCCOCC(F)(F)F)=O)=C(C)C1=O QGDLWQFFQHCHEJ-UHFFFAOYSA-N 0.000 description 1
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
• 108010053070 Glutathione Disulfide Proteins 0.000 description 1
• 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 description 1
• 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 208000026072 Motor neurone disease Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 208000002903 Thalassemia Diseases 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
• 201000007998 methylmalonic aciduria and homocystinuria type cblC Diseases 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 230000036284 oxygen consumption Effects 0.000 description 1
• 229950007002 phosphocreatine Drugs 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1